A deep dive into iPledge changes with John Barbieri, MD
Beneath the Surface
In this episode, guest John Barbieri, MD, MBA, discusses the FDA’s 2023 proposed changes to the iPledge system and the impacts of clinical trials and treatments on patients with hormonal acne. • Intro 0:28 • John Barbieri, MD, MBA 0:42 • What does it mean to have a conditional recommendation, and why is this considered “controversial”? 1:50 • What are the reasons, such as limitations of use, that lead to a conditional recommendation? 2:48 • How would you implement these care guidelines into clinical...
info_outline
The science behind vitiligo with John Harris, MD, PhD
Beneath the Surface
In this episode, guest John E. Harris, MD, PhD, discusses how vitiligo occurs and how dermatologists can navigate the vitiligo treatment landscape. • Intro 0:28 • John E. Harris, MD, PhD 0:41 • How does vitiligo occur, and what is the basic science behind it? 1:08 • Are there any known triggers of this condition in people who have genetic susceptibility to it? 3:19 • How does drug-induced vitiligo occur in people? 4:42 • When you see a patient with vitiligo, how do you approach the...
info_outline
Exploring sodium’s effect on dermatologic disease with Katrina Abuabara, MD
Beneath the Surface
In this episode, guest Katrina Abuabara, MD, discusses the possible role of sodium in dermatologic diseases and how dermatologists can make recommendations for patients’ sodium intake. • Intro 0:29 • Katrina Abuabara, MD, MA, MSCE 0:41 • What made you think about the question behind your paper on ? 1:08 • How do you measure sodium in the skin? 2:49 • In which dermatologic diseases are abnormal sodium in the skin playing a significant role? 3:36 • Is there any evidence that changing...
info_outline
Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD
Beneath the Surface
In this episode, guest Brett King, MD, PhD, discusses the efficacy of Janus kinase (JAK) inhibitors for the treatment of alopecia areata and conversations with patients surrounding medical pauses. • Intro 0:29 • Brett King, MD, PhD 0:41 • When a patient comes to the office with alopecia areata and want to go on a JAK inhibitor, how do you counsel them about their likelihood for significant hair regrowth? 1:35 • Is your estimate of roughly fifty percent rate from data, or from your own experiences with patients? 6:03 •...
info_outline
How to embrace AI responsibly with Roxana Daneshjou, MD, PhD
Beneath the Surface
In this episode, guest Roxana Daneshjou, MD, PhD, discusses the role of artificial intelligence in dermatology practice, and the future of AI models in medicine. • Intro 0:29 • Roxana Daneshjou, MD, PhD 0:45 • What is artificial intelligence? 1:10 • What led to this largely academic endeavor becoming deployable? 2:36 • How is AI being deployed in health care today? 5:36 • What is currently deployable about AI in the dermatology space? 7:56 • How long do you think it will be...
info_outlineIn this episode, guest John E. Harris, MD, PhD, discusses how vitiligo occurs and how dermatologists can navigate the vitiligo treatment landscape.
• Intro 0:28
• John E. Harris, MD, PhD 0:41
• How does vitiligo occur, and what is the basic science behind it? 1:08
• Are there any known triggers of this condition in people who have genetic susceptibility to it? 3:19
• How does drug-induced vitiligo occur in people? 4:42
• When you see a patient with vitiligo, how do you approach the patient to establish a diagnosis? 6:03
• Given that this is an autoimmune disease, do you routinely screen vitiligo patients for things like their thyroid function and B12 levels? 9:54
• What about the pernicious anemia aspect of things? 10:36
• Tell us a little bit about the treatment landscape, and how you counsel patients. 12:26
• Who is a good candidate for these new treatment options, and what success rate do you quote over a period of time? 14:06
• When do you bring patients back in for follow-ups? 14:59
• How often are you administering combination therapy? 15:30
• Does narrow band UVB work synergistically with other therapies, or is it more of an added measure? 16:20
• How do you manage patients who have early extensive active vitiligo? 17:08
• If someone has facial vitiligo in a non-pigmented area, do you still treat that patient? 18:01
• Thank you, Dr. Harris. 19:09
John E. Harris, MD, PhD, is professor and chair of the Department of Dermatology and founding director of the Vitiligo Clinical Research Center, as well as the founding director of the Autoimmune Therapeutics Institute at UMass Chan Medical School.
We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn.
For more, be sure to visit the Beneath the Surface video blog on Healio.com.
Disclosures: Gelfand reports no relevant financial disclosures. Harris reports having financial relationships with AbbVie, Aclaris Therapeutics, Admirx, Aldena Therapeutics, Almirall, AnaptysBio, Avita, BiologicsMD, Boston Pharma, Celgene, Cogen Therapeutics, Dermavant, Dermira, EMD Serono, Expert Institute, Frazier Management, Genzyme/Sanofi, Incyte, Janssen, LEO Pharma, Methuselah Health, NIRA Biosciences, Pandion, Pfizer, Rheos Medicines, Sonoma Biotherapeutics, Stiefel/GSK, Sun Pharmaceuticals, Temprian Therapeutics, TeVido BioDevices, 3rd Rock Ventures, TWi Biotech, Villaris Therapeutics and Vimela Therapeutics.